top of page
The Professional Network for Healthcare Experts
FDA approves Novartis Rhapsido as first treatment for symptomatic dermographism
Novartis has secured FDA approval for Rhapsido as the first treatment specifically approved for symptomatic dermographism in adults inadequately controlled by H1 antihistamines.
nuaxia
21 hours ago2 min read
FDA expands Jaypirca approval to first-line treatment of CLL and SLL
The FDA has moved Jaypirca into first-line CLL and SLL treatment following Phase III data showing a substantial reduction in the risk of disease progression or death.
nuaxia
4 days ago2 min read
bottom of page